Search results for "Pimasertib"

showing 3 items of 3 documents

Pimasertib (PIM) versus dacarbazine (DTIC) in patients (pts) with cutaneous NRAS melanoma: a controlled, open-label phase II trial with crossover

2016

0301 basic medicineOncologyNeuroblastoma RAS viral oncogene homologmedicine.medical_specialtybusiness.industryMelanomaHematologymedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicinemedicinePimasertibIn patientDacarbazine - DTICOpen labelbusinessAnnals of Oncology
researchProduct

Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover

2020

This study investigated the efficacy and safety of pimasertib (MEK1/MEK2 inhibitor) versus dacarbazine (DTIC) in patients with untreated NRAS-mutated melanoma. Phase II, multicenter, open-label trial. Patients with unresectable, stage IIIc/IVM1 NRAS-mutated cutaneous melanoma were randomized 2:1 to pimasertib (60 mg

Cancer ResearchGastroenterologypimasertiblaw.invention0302 clinical medicineRandomized controlled triallawClinical endpoint030212 general & internal medicineMalignant melanomaHazard ratioProgression-free survivalSciences bio-médicales et agricoleslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthDacarbazineOncology[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology030220 oncology & carcinogenesismedicine.symptomPimasertibmedicine.drugQuality of lifemedicine.medical_specialtyNauseaDacarbazinemalignant melanomadacarbazine[SDV.CAN]Life Sciences [q-bio]/CancerN-(2 3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamideNeutropeniaN-(23-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamidelcsh:RC254-282Article03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerInternal medicinemedicineProgression-free survivalAdverse effectbusiness.industry[SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatologymedicine.diseaseadverse eventsCancérologiequality of lifeAdverse events[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacologybusinessprogression-free survival[SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
researchProduct

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

2015

BACKGROUND: The mitogen-activated protein kinase (MAPK) pathway has been implicated in the molecular pathogenesis of human cancers, including metastatic colorectal cancer (mCRC). This provides a rationale for the development of MAPK-targeted agents such as pimasertib. METHODS: Patients with KRAS mutant mCRC were treated in the second-line setting with FOLFIRI (5-fluorouracil/folinic acid/irinotecan) plus pimasertib. The primary objective of the safety run-in phase was to determine the maximum-tolerated dose (MTD) and the recommended phase II dose of pimasertib combined with FOLFIRI. RESULTS: Sixteen patients were enrolled in the trial. Ten and six patients were treated daily with 45 and 60 …

MaleCancer ResearchColorectal cancermedicine.medical_treatmentLeucovorinColorectal NeoplasmPharmacologymedicine.disease_causepimasertibcombination therapyAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Metastasiscombination therapy second-line treatmentAged 80 and overProto-Oncogene ProteinCetuximabKRAS-mutated metastatic colorectal cancerMedicine (all)MEK inhibitorMiddle AgedNeoplasm MetastasiTreatment OutcomeOncologyFluorouracilFOLFIRISecond-line treatmentFemaleFluorouracilKRASColorectal NeoplasmsPimasertibHumanmedicine.drugNiacinamideProto-Oncogene Proteins p21(ras)FOLFIRIProto-Oncogene ProteinsmedicineHumansCombination therapyneoplasmsAgedChemotherapyMEK inhibitorAntineoplastic Combined Chemotherapy Protocolbusiness.industryKRAS -mutated metastatic colorectal cancerGenes raras Proteinmedicine.diseasedigestive system diseasesGenes rassecond-line treatmentMutationras ProteinsClinical StudyCancer researchCamptothecinHuman medicinebusinessCamptothecinThe British journal of cancer
researchProduct